68例儿童、青少年非霍奇金淋巴瘤临床及预后分析

发布时间：2018-03-06 18:06

  本文选题：儿童　切入点：青少年　出处：《南京医科大学学报(自然科学版)》2017年11期 　论文类型：期刊论文

【摘要】：目的:总结分析儿童、青少年非霍奇金淋巴瘤(non-Hodgkin lymphoma,NHL)临床特征、预后因素、化疗方案及疗效。方法:选取南京医科大学第一附属医院2009年9月—2015年12月收治的68例NHL患者,收集临床资料,总体生存(overall survival,OS)、无事件生存(event free survival,EFS)统计分析用Kaplan-Meier方法,组间生存情况比较用Log-rank检验。结果:68例NHL患者中,男45例,女23例,中位年龄17岁(2~20岁);包括成熟B-NHL 33例,NK/T-NHL 22例,淋巴母细胞淋巴瘤13例。58例化疗患者进行了生存分析,1年、3年、5年OS率分别为80.7%、70.5%和70.5%,EFS率分别为61.1%、56.3%和56.3%。29例成熟B-NHL接受利妥昔单抗组与未接受利妥昔单抗治疗组5年OS率分别为93.3%和66.7%(P=0.038);造血干细胞移植(hematopoietic stem cell transplantation,HSCT)组与非HSCT组5年EFS率分别为80.0%和46.8%(P=0.050)。患者疾病分期、疾病免疫分型、白蛋白水平与OS有关(P=0.050)。结论:儿童、青少年NHL多见于男性,Ⅲ、Ⅳ期比例高,利妥昔单抗靶向治疗、HSCT可提高OS和EFS,预后与疾病分期、免疫分型和白蛋白水平相关。
[Abstract]:Objective: to summarize and analyze the clinical features, prognostic factors, chemotherapy regimen and curative effect of non-Hodgkin lymphoma NHL in children and adolescents. Methods: 68 patients with NHL were selected from September 2009 to December 2015 in the first affiliated Hospital of Nanjing Medical University. Clinical data were collected, total survival free survival was analyzed by Kaplan-Meier method and Log-rank test was used to compare survival among groups. Results among 68 NHL patients, 45 were male and 23 were female. The median age was 17 years old and 20 years old, including 33 mature B-NHL cases and 22 NKR / T-NHL cases. A survival analysis was conducted in 13 patients with lymphoblastic lymphoma. The OS rates for 1 year, 3 years and 5 years were 80.775% and 70.5%, respectively. The EFS rates were 61.1% and 56.3%, respectively. 29 cases of mature B-NHL received rituximab and no rituximab for 5 years. The EFS rates of hematopoietic stem cell translocation in hematopoietic stem cell transplantation group and non-#en2# group were 80.0% and 46.8% respectively. Conclusion: NHL in children and adolescents is more common in males and higher in stage 鈪，

本文编号：1575906